Johnson and Johson to discontinue late-stage study of RSV vaccine
Pfizer and GSK are running a tight race to tap into the RSV vaccine market, which is estimated to be more than $5 billion and could exceed $10 billion by 2030, according to analysts.
Advertisement
New Delhi: Johnson & Johnson said it will discontinue the late-stage study of its experimental respiratory syncytial virus (RSV) adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus.
J&J made the decision in order "to focus on medicines with the greatest potential benefit to patients," the company said on Wednesday.
The drugmaker, which started the global study in 2021 in more than 27,000 adults aged 60 years and older, did not provide any further details about the trial.
There is currently no approved vaccine to prevent lower respiratory tract disease caused by RSV in older adults. It is responsible for 14,000 deaths in adults aged 65 and older annually in the United States, according to government data.
Pfizer Inc and GSK's RSV vaccines gained the backing of a panel of U.S. Food and Drug Administration advisers in late February and early March, bringing them a step closer to approval in the United States. The health regulator is expected to decide on the two vaccines by May.
Pfizer and GSK are running a tight race to tap into the RSV vaccine market, which is estimated to be more than $5 billion and could exceed $10 billion by 2030, according to analysts.
J&J's late-stage study was being conducted in more than 300 sites across the U.S., the UK, Canada, Australia, Chile, Brazil and China, among other countries, according to a government registry of clinical trials.
The company said it plans to share results from the late-stage study with the scientific community.
J&J started the study following positive results from a mid-stage trial, which showed the vaccine was 80 percent effective in protecting against lower respiratory tract disease caused by RSV. The company's shares were up nearly 1 percent at $153.08 on Wednesday.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.